Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa

Biochemical Pharmacology

Volumn 65, Issue 9, 2003, Pages 1407-1418

  Liang, Amy M ^a   Light, David R ^a   Kochanny, Monica ^a   Rumennik, Galina ^a   Trinh, Lan ^a   Lentz, Dao ^a   Post, Joseph ^a   Morser, John ^a   Snider, Michael ^a  

^a BAYER AG   (Germany)

Author keywords

Anticoagulant; Benzothiophene anthranilamide; Human factor Xa

Indexed keywords

3 CHLORO N [2 [[(4 FLUOROPHENYL)AMINO]CARBONYL] 4 METHYLPHENYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; AMIDINE; ANILIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DEXTRO ISOLEUCYLPROLYLARGININE 4 NITROANILIDE; DEXTRO PROLYLPHENYLALANYLARGININE 4 NITROANILIDE; DEXTRO VALYLLEUCYLARGININE 4 NITROANILIDE; N BENZOYLISOLEUCYL GAMMA GLUTAMYLGLYCYLARGININE 4 NITROANILIDE; N BENZOYLISOLEUCYLGLUTAMYLGLYCYLARGININE 4 NITROANILIDE; PHOSPHOLIPID; PROTHROMBIN; PYROGLUTAMYLGLYCYLARGININE 4 NITROANILIDE; PYROGLUTAMYLPROLYLARGININE 4 NITROANILIDE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); DILUTION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; PRIORITY JOURNAL;

EID: 0038065501     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00084-4     Document Type: Article

References (44)

1. Vlasuk G.P., Ramjit D., Fujita T., Dunwiddie C.T., Nutt E.M., Smith D.E., Shebuski R.J. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemost. 65:1991;257-262.
2. Zhu B.Y., Scarborough R.M. Recent advances in inhibitors of factor Xa in the prothrombinase complex. Curr. Opin. Cardiovasc. Pulmon. Renal Invest. Drugs. 1:1999;63-87.
3. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74:1995;635-639.
4. Kawasaki T., Sato K., Sakai Y., Hirayama F., Koshio H., Taniuchi Y., Matsumoto Y. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemost. 79:1998;410-416.
5. Sinha U., Ku P., Malinowski J., Zhu B.Y., Scarborough R.M., Marlowe C.K., Wong P.W., Lin P.H., Hollenbach S.J. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur. J. Pharmacol. 395:2000;51-59.
6. Abendschein D.R., Baum P.K., Martin D.J., Vergona R., Post J., Rumennik G., Sullivan M.E., Eisenberg P.R., Light D.R. Effect of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J. Cardiovasc. Pharmacol. 35:2000;796-805.
7. Heran C., Morgan S., Kasiewski C., Bostwick J., Bentley R., Klein S., Chu V., Brown K., Colussi D., Czekaj M., Perrone M., Leadley R. Jr. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur. J. Pharmacol. 389:2000;201-207.
8. Abendschein D.R., Baum P.K., Verhallen P.R., Eisenberg P.R., Sullivan M.E., Light D.R. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-hr patency after coronary fibrinolysis in dogs. J. Pharmacol. Exp. Ther. 296:2001;567-572.
9. Nagahara T., Yokoyama Y., Inamura K., Katakura S., Komoriya S., Yamaguchi H., Hara T., Iwamoto M. Dibasic (amidinoaryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J. Med. Chem. 37:1994;1200-1207.
10. Taniuchi Y., Sakai Y., Hisamichi N., Kayama M., Mano Y., Sato K., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb. Haemost. 79:1998;543-548.
11. Phillips G.B., Buckman B.O., Davey D.D., Eagen K.A., Guilford W.J., Hinchman J., Ho E., Koovakkat S., Liang A., Light D.R., Mohan R., Ng H.P., Post J.M., Shaw K.J., Smith D., Subramanyam B., Sullivan M.E., Trinh L., Vergona R., Walters J., White K., Whitlow M., Wu S., Xu W., Morrissey M.M. Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5- difluoro-6- [3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]- N-methylglycine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. 41:1998;3557-3562.
12. Quan M.L., Ellis C.D., Liauw A.Y., Alexander R.S., Knabb R.M., Lam G., Wright M.R., Wong P.C., Wexler R.R. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. J. Med. Chem. 42:1999;2760-2773.
13. Han Q., Dominguez C., Stouten P.F.W., Park J.M., Duffy D.E., Galemmo R.A. Jr., Rossi K.A., Alexander R.S., Smallwood A.M., Wong P.C., Wright M.M., Luettgen J.M., Knabb R.M., Wexler R.R. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. J. Med. Chem. 43:2000;4398-4415.
14. Chu V., Brown K., Colussi D., Choi Y-M., Green D., Pauls H.W., Spada A.P., Perrone M.H., Leadley R.L. Jr., Dunwiddie C.T. In vitro characterization of a novel factor Xa inhibitor, RPR 130737. Thromb. Res. 99:2000;71-82.
15. Wiley M.R., Weir L.C., Briggs S., Bryan N.A., Buben J., Campbell C., Chirgadze N.Y., Conrad R.C., Craft T.J., Ficorilli J.V., Franciskovich J.B., Froelich L.L., Gifford-Moore D.S., Goodson T. Jr., Herron D.K., Klimkowski V.J., Kurz K.D., Kyle J.A., Masters J.J., Ratz A.M., Milot G., Shuman R.T., Smith T., Smith G.F., Tebbe A.L., Tinsley J.M., Towner R.D., Wilson A., Yee Y.K. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J. Med. Chem. 43:2000;883-899.
16. Dudley D.A., Bunker A.M., Chi L., Cody W.L., Holland D.R., Ignasiak D.P., Janiczek-Dolphin N., McClanahan T.B., Mertz T.E., Narasimhan L.S., Rapundalo S.T., Trautschold J.A., Van Huis C.A., Edmunds J.J. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. J. Med. Chem. 43:2000;4063-4070.
17. Fevig J.M., Cacciola J., Alexander R.S., Knabb R.M., Lam G.N., Wong P.C., Wexler R.R. Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa. Bioorg. Med. Chem. Lett. 8:1998;3143-3148.
18. Fevig J.M., Buriak J. Jr., Stouten P.F.W., Knabb R.M., Lam G.N., Wong P.C., Wexler R.R. Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa. Bioorg. Med. Chem. Lett. 9:1999;1195-1200.
19. Faull A.W., Mayo C.M., Preston J., Stocker A. Novel aminoheterocyclic derivatives as inhibitors of factor Xa. Exp. Opin. Ther. Patents. 6:1996;795-799.
20. Choi-Sledeski Y.M., Becker M.R., Green D.M., Davis R., Ewing W.R., Mason H.J., Ly C., Spada A., Liang G., Cheney D., Barton J., Chu V., Brown K., Colussi D., Bentley R., Leadley R., Dunwiddie C., Pauls H.W. Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa. Bioorg. Med. Chem. Lett. 9:1999;2539-2544.
21. Masters J.J., Franciskovich J.B., Tinsley J.M., Campbell C., Campbell J.B., Craf T.J., Froelich L.L., Gifford-Moore D.S., Hay L.A., Herron D.K., Klimkowski V.J., Kurz K.D., Metz J.T., Ratz A.M., Shuman R.T., Smith G.F., Smith Y., Towner R.D., Wiley M.R., Wilson A., Yee Y.K. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity. J. Med. Chem. 43:2000;2087-2092.
22. Phillips G., Davey D.D., Eagen K.A., Koovakkat S.K., Liang A., Ng H.P., Pinkerton M., Trinh L., Whitlow M., Beatty A.M., Morrissey M.M. Design, synthesis and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J. Med. Chem. 42:1999;1749-1756.
23. Chou Y.L., Davey D.D., Eagen K.A., Griedel B.D., Karanjawala R., Phillips G.B., Sacchi K.L., Shaw K.J., Wu S.C., Lentz D., Liang A., Trinh L., Morrissey M.M., Kochanny M.J. Structural-activity relationship of substituted benzothiophene-anthranilamide factor Xa inhibitors. Bioorg. Med. Chem. Lett. 13:2003;507-511.
24. Post J.M., Sullivan M.E., Abendschein D., Ewing J., Hinchman J.W., Light D.R. Human in vitro pharmacodynamic profile of the selective factor Xa inhibitor ZK-807834 (CI-1031). Thromb. Res. 105:2002;347-352.
25. Devlin J.J., Liang A., Trinh L., Polokoff M.A., Senator D., Zheng W., Kondracki J., Kretschmer P.J., Morser J., Lipson S.E., Spann R., Loughlin J.A., Dunn K.V., Morrissey M.M. High capacity screening of pooled compounds: identification of the active compound without re-assay of pool members. Drug Dev. Res. 37:1996;80-85.
26. Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K dependent coagulation factors. Crit. Rev. Eukaryot. Gene Expr. 9:1999;59-88.
27. Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: Wiley; 1975.
28. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J. 137:1974;143-144.
29. Light D., Liang A., Rumennik G., Clarke J., McLean K., Post J., Trinh L., Phillips G., Davey D., Guilford W., Morser J., Morrissey M., Sullivan M. In vitro inhibition of factor Xa (Xa) and prothrombinase (PTase) by BX-807834 (BX), a potent, selective active site inhibitor. FASEB J. 12:1998;A719.
30. Hara T., Yokoyama A., Ishihara H., Yokoyama Y., Nagahara T., Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemost. 71:1994;314-319.
31. Adler M., Davey D.D., Phillips G.B., Kim S.U., Jancarik J., Rumennik G., Light D.R., Whitlow M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry. 39:2000;12534-12542.
32. Feng D.M., Gardell S.J., Lewis S.D., Bock M.G., Chen Z., Freidinger R.M., Naylor-Olsen A.M., Ramjit H.G., Woltman R., Baskin E.P., Lynch J.J., Lucas R., Shafer J.A., Dancheck K.B., Chen I.W., Mao S.S., Krueger J.A., Hare T.R., Mulichak A.M., Vacca J.P.J. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J. Med. Chem. 40:1997;3726-3733.
33. Faull AW. Aminoheterocyclic compounds with antithrombotic/anticoagulant effect. Patent Corporation Treaty Publication No. WO-09729104; 1997.
34. Smithers MJ, Preston J, Stocker A. Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents. Patent Corporation Treaty Publication No. WO-09728129; 1997.
35. Preston J., Stocker A., Tumer P., Smithers M.J., Rayner J.W. Heterocycle derivatives that inhibit factor Xa. Exp. Opin. Ther. Patents. 8:1998;1361-1367.
36. Tawada H, Ho F, Moriya N, Terashita Z. Sulfonaimde derivatives, their production and use. Patent Corporation Treaty Publication No. WO-09854164; 1998.
37. 2-Aroylanthranilamide inhibitors of human factor Xa. J. Med. Chem. 43:2000;873-882.
38. Pinto D.J.P., Orwat M.J., Wang S., Fevig J.M., Quan M.L., Amparo E., Cacciola J., Rossi K.A., Alexander R.S., Smallwood A.M., Luettgen J.M., Liang L., Aungst B.J., Wright M.R., Knabb R.M., Wong P.C., Wexler R.R., Lam P.Y.S. Discovery of 1-[3-(aminomethyl)phenyl]-N- [3-fluoro-2′(methylsulfony)- [1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 44:2001;566-578.
39. Shrader W.D., Young W.B., Sprengeler P.A., Sangalang J.C., Elrod K., Carr G. Neutral inhibitors of the serine protease factor Xa. Bioorg. Med. Chem. Lett. 11:2001;1801-1804.
40. Hirayama F., Koshio H., Katayama N., Kurihara H., Taniuchi Y., Sato K., Hisamichi N., Sakai-Moritani Y., Kawasaki T., Matsumoto Y., Yanagisawa I. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor. Bioorg. Med. Chem. 10:2002;1509-1523.
41. Bode W., Turk D., Karshikov A. The refined 1.9-Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1:1992;426-471.
42. Stockel-Maschek A., Mrestani-Klaus C., Stiebitz B., Demuth H., Neubert K. Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim. Biophys. Acta. 1479:2000;15-31.
43. Herron D.K., Goodson T. Jr., Wiley M.R., Weir L.C., Kyle J.A., Yee Y.K., Tebbe A.L., Tinsley J.M., Mendel D., Masters J.J., Franciskovich J.B., Sawyer J.S., Beight D.W., Ratz A.M., Milot G., Hall S.E., Klimkowski V.J., Wikel J.H., Eastwood B.J., Towner R.D., Gifford-Moore D.S., Craft T.J., Smith G.F. 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J. Med. Chem. 43:2000;859-872.
44. Maignan S., Guilloteau J.P., Pouzieux S., Choi-Sledeski Y.M., Becker M.R., Klein S.I., Ewing W.R., Pauls H.W., Spada A.P., Mikol V. Crystal structures of human factor Xa complexed with potent inhibitors. J. Med. Chem. 43:2000;3226-3232.